Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | CFO, Secretary, Treasurer | May 16, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date May 16, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2032-05-16 | Direct | 900,000 |
Reported balance
After 2022-05-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-16 · Grant · Acquired 900,000 · Balance 900,000 F1: Options were awarded by the Board of Directions as part of Mr. Chen's employment agreement. F2: The options will best over a three-year period, commencing one year from the date of issuance. The first third will vest on May 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Options were awarded by the Board of Directions as part of Mr. Chen's employment agreement.
F2: The options will best over a three-year period, commencing one year from the date of issuance. The first third will vest on May 16, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed Jul 7, 2022 20:53 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantOptions · Derivative | 900,000 | $0.04 Strike: $0.04 | $36,000.00 |
DisclosureSEC source: 0001931826-22-000002 · primary_doc.xml · derivative · entry 1 Chen Robert C J · CIK 0001931826 · CFO, Secretary, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2032-05-16 F1 · shares: Options were awarded by the Board of Directions as part of Mr. Chen's employment agreement. F2 · derivative.exercise_date: The options will best over a three-year period, commencing one year from the date of issuance. The first third will vest on May 16, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.